Logo image of BAYN.DE

BAYER AG-REG (BAYN.DE) Stock Fundamental Analysis

FRA:BAYN - Deutsche Boerse Ag - DE000BAY0017 - Common Stock - Currency: EUR

26.62  -0.31 (-1.15%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to BAYN. BAYN was compared to 51 industry peers in the Pharmaceuticals industry. BAYN has a bad profitability rating. Also its financial health evaluation is rather negative. BAYN is valued quite cheap, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year BAYN was profitable.
In the past year BAYN had a positive cash flow from operations.
In multiple years BAYN reported negative net income over the last 5 years.
BAYN had a positive operating cash flow in each of the past 5 years.
BAYN.DE Yearly Net Income VS EBIT VS OCF VS FCFBAYN.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5B -5B -10B

1.2 Ratios

BAYN has a Return On Assets of -2.98%. This is in the lower half of the industry: BAYN underperforms 70.59% of its industry peers.
The Return On Equity of BAYN (-10.03%) is worse than 70.59% of its industry peers.
Industry RankSector Rank
ROA -2.98%
ROE -10.03%
ROIC N/A
ROA(3y)-0.5%
ROA(5y)-1.93%
ROE(3y)-2.08%
ROE(5y)-7.52%
ROIC(3y)N/A
ROIC(5y)N/A
BAYN.DE Yearly ROA, ROE, ROICBAYN.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 -20 -30

1.3 Margins

BAYN's Operating Margin has declined in the last couple of years.
With a Gross Margin value of 53.99%, BAYN is not doing good in the industry: 72.55% of the companies in the same industry are doing better.
In the last couple of years the Gross Margin of BAYN has declined.
The Profit Margin and Operating Margin are not available for BAYN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 53.99%
OM growth 3Y-18.1%
OM growth 5Y-4.34%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.21%
GM growth 5Y-1.81%
BAYN.DE Yearly Profit, Operating, Gross MarginsBAYN.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60

More info and screens

2

2. Health

2.1 Basic Checks

BAYN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, BAYN has about the same amount of shares outstanding.
The number of shares outstanding for BAYN remains at a similar level compared to 5 years ago.
The debt/assets ratio for BAYN has been reduced compared to a year ago.
BAYN.DE Yearly Shares OutstandingBAYN.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M
BAYN.DE Yearly Total Debt VS Total AssetsBAYN.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20B 40B 60B 80B 100B

2.2 Solvency

BAYN has an Altman-Z score of 0.83. This is a bad value and indicates that BAYN is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of BAYN (0.83) is worse than 68.63% of its industry peers.
The Debt to FCF ratio of BAYN is 6.81, which is on the high side as it means it would take BAYN, 6.81 years of fcf income to pay off all of its debts.
BAYN has a Debt to FCF ratio (6.81) which is in line with its industry peers.
BAYN has a Debt/Equity ratio of 1.08. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 1.08, BAYN is not doing good in the industry: 66.67% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 1.08
Debt/FCF 6.81
Altman-Z 0.83
ROIC/WACCN/A
WACC5.95%
BAYN.DE Yearly LT Debt VS Equity VS FCFBAYN.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B 40B

2.3 Liquidity

BAYN has a Current Ratio of 1.25. This is a normal value and indicates that BAYN is financially healthy and should not expect problems in meeting its short term obligations.
BAYN has a Current ratio of 1.25. This is in the lower half of the industry: BAYN underperforms 74.51% of its industry peers.
A Quick Ratio of 0.79 indicates that BAYN may have some problems paying its short term obligations.
The Quick ratio of BAYN (0.79) is worse than 68.63% of its industry peers.
Industry RankSector Rank
Current Ratio 1.25
Quick Ratio 0.79
BAYN.DE Yearly Current Assets VS Current LiabilitesBAYN.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B

More info and screens

3

3. Growth

3.1 Past

The earnings per share for BAYN have decreased strongly by -24.72% in the last year.
The Earnings Per Share has been decreasing by -5.27% on average over the past years.
BAYN shows a decrease in Revenue. In the last year, the revenue decreased by -0.92%.
BAYN shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 1.37% yearly.
EPS 1Y (TTM)-24.72%
EPS 3Y-8.12%
EPS 5Y-5.27%
EPS Q2Q%-11.7%
Revenue 1Y (TTM)-0.92%
Revenue growth 3Y1.87%
Revenue growth 5Y1.37%
Sales Q2Q%-0.2%

3.2 Future

Based on estimates for the next years, BAYN will show a small growth in Earnings Per Share. The EPS will grow by 2.44% on average per year.
The Revenue is expected to grow by 1.43% on average over the next years.
EPS Next Y-8.65%
EPS Next 2Y-1.15%
EPS Next 3Y1.51%
EPS Next 5Y2.44%
Revenue Next Year-0.13%
Revenue Next 2Y0.7%
Revenue Next 3Y1.06%
Revenue Next 5Y1.43%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
BAYN.DE Yearly Revenue VS EstimatesBAYN.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 10B 20B 30B 40B 50B
BAYN.DE Yearly EPS VS EstimatesBAYN.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2 4 6

More info and screens

7

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 5.64 indicates a rather cheap valuation of BAYN.
BAYN's Price/Earnings ratio is rather cheap when compared to the industry. BAYN is cheaper than 94.12% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 26.34. BAYN is valued rather cheaply when compared to this.
A Price/Forward Earnings ratio of 5.39 indicates a rather cheap valuation of BAYN.
Based on the Price/Forward Earnings ratio, BAYN is valued cheaply inside the industry as 96.08% of the companies are valued more expensively.
BAYN is valuated cheaply when we compare the Price/Forward Earnings ratio to 22.19, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 5.64
Fwd PE 5.39
BAYN.DE Price Earnings VS Forward Price EarningsBAYN.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

BAYN's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. BAYN is cheaper than 76.47% of the companies in the same industry.
98.04% of the companies in the same industry are more expensive than BAYN, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 4.52
EV/EBITDA 7.38
BAYN.DE Per share dataBAYN.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.15%
EPS Next 3Y1.51%

More info and screens

1

5. Dividend

5.1 Amount

BAYN has a yearly dividend return of 0.40%, which is pretty low.
Compared to an average industry Dividend Yield of 2.92, BAYN has a dividend in line with its industry peers.
Compared to an average S&P500 Dividend Yield of 2.40, BAYN's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 0.4%

5.2 History

The dividend of BAYN decreases each year by -45.34%.
Dividend Growth(5Y)-45.34%
Div Incr Years0
Div Non Decr Years3
BAYN.DE Yearly Dividends per shareBAYN.DE Yearly Dividends per shareYearly Dividends per share 2019 2020 2021 2022 2023 2024 2025 0.5 1 1.5 2 2.5

5.3 Sustainability

The earnings of BAYN are negative and hence is the payout ratio. BAYN will probably not be able to sustain this dividend level.
DP-4.03%
EPS Next 2Y-1.15%
EPS Next 3Y1.51%
BAYN.DE Yearly Income VS Free CF VS DividendBAYN.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5B -5B -10B

More info and screens

BAYER AG-REG

FRA:BAYN (6/20/2025, 5:09:40 PM)

26.62

-0.31 (-1.15%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-13 2025-05-13/bmo
Earnings (Next)08-06 2025-08-06
Inst Owners41.07%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap26.15B
Analysts68.97
Price Target28.05 (5.37%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0.4%
Yearly Dividend0.13
Dividend Growth(5Y)-45.34%
DP-4.03%
Div Incr Years0
Div Non Decr Years3
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)2.63%
Min EPS beat(2)1.86%
Max EPS beat(2)3.41%
EPS beat(4)3
Avg EPS beat(4)-1.9%
Min EPS beat(4)-17.26%
Max EPS beat(4)4.42%
EPS beat(8)5
Avg EPS beat(8)-2.92%
EPS beat(12)8
Avg EPS beat(12)-2.14%
EPS beat(16)12
Avg EPS beat(16)1.92%
Revenue beat(2)1
Avg Revenue beat(2)0.4%
Min Revenue beat(2)-0.98%
Max Revenue beat(2)1.79%
Revenue beat(4)2
Avg Revenue beat(4)-0.64%
Min Revenue beat(4)-3.42%
Max Revenue beat(4)1.79%
Revenue beat(8)2
Avg Revenue beat(8)-2.63%
Revenue beat(12)4
Avg Revenue beat(12)-2.01%
Revenue beat(16)8
Avg Revenue beat(16)-0.66%
PT rev (1m)2.01%
PT rev (3m)1.36%
EPS NQ rev (1m)-10.26%
EPS NQ rev (3m)-10.26%
EPS NY rev (1m)0%
EPS NY rev (3m)-2.05%
Revenue NQ rev (1m)-2.06%
Revenue NQ rev (3m)-2.06%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.25%
Valuation
Industry RankSector Rank
PE 5.64
Fwd PE 5.39
P/S 0.56
P/FCF 4.52
P/OCF 3.08
P/B 0.81
P/tB N/A
EV/EBITDA 7.38
EPS(TTM)4.72
EY17.73%
EPS(NY)4.93
Fwd EY18.54%
FCF(TTM)5.88
FCFY22.11%
OCF(TTM)8.65
OCFY32.51%
SpS47.41
BVpS33.03
TBVpS-18.52
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -2.98%
ROE -10.03%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 53.99%
FCFM 12.41%
ROA(3y)-0.5%
ROA(5y)-1.93%
ROE(3y)-2.08%
ROE(5y)-7.52%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)7.82%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-18.1%
OM growth 5Y-4.34%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.21%
GM growth 5Y-1.81%
F-Score3
Asset Turnover0.43
Health
Industry RankSector Rank
Debt/Equity 1.08
Debt/FCF 6.81
Debt/EBITDA 4.37
Cap/Depr 30.76%
Cap/Sales 5.84%
Interest Coverage N/A
Cash Conversion 106.2%
Profit Quality N/A
Current Ratio 1.25
Quick Ratio 0.79
Altman-Z 0.83
F-Score3
WACC5.95%
ROIC/WACCN/A
Cap/Depr(3y)34.81%
Cap/Depr(5y)41.62%
Cap/Sales(3y)5.85%
Cap/Sales(5y)5.86%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-24.72%
EPS 3Y-8.12%
EPS 5Y-5.27%
EPS Q2Q%-11.7%
EPS Next Y-8.65%
EPS Next 2Y-1.15%
EPS Next 3Y1.51%
EPS Next 5Y2.44%
Revenue 1Y (TTM)-0.92%
Revenue growth 3Y1.87%
Revenue growth 5Y1.37%
Sales Q2Q%-0.2%
Revenue Next Year-0.13%
Revenue Next 2Y0.7%
Revenue Next 3Y1.06%
Revenue Next 5Y1.43%
EBIT growth 1Y-214.77%
EBIT growth 3Y-16.56%
EBIT growth 5Y-3.03%
EBIT Next Year63.3%
EBIT Next 3Y21.17%
EBIT Next 5Y11%
FCF growth 1Y380.55%
FCF growth 3Y22.16%
FCF growth 5Y-3.69%
OCF growth 1Y99.13%
OCF growth 3Y12.83%
OCF growth 5Y-2.09%